Triple‐negative breast cancer: Present challenges and new perspectives

Podo, Franca; Buydens, L.M.C.; Degani, Hadassa; Hilhorst, Riet; Klipp, Edda; Gribbestad, Ingrid S.; Huffel, Sabine Van; Laarhoven, Hanneke W. M. van; Luts, Jan; Monleón, Daniel; Postma, G.J.; Schneiderhan‐Marra, Nicole; Santoro, Filippo; Wouters, Hans; Russnes, Hege G.; Sørlie, Thérese; Tagliabue, Elda; Børresen-Dale, Anne Lise

doi:10.1016/j.molonc.2010.04.006

Cited by 268 publications

(228 citation statements)

References 208 publications

(301 reference statements)

Supporting

Mentioning

221

Contrasting

Unclassified

Order By: Relevance

“…Patients were excluded if either study occurred after any treatment or if the timing of therapy with respect to these studies as a focus of interest because of its aggressive natural history. Though it accounts for only 10%-20% of all breast cancers, TN breast cancer consists of a relatively large proportion of cancer deaths and has a high rate of distant metastases at diagnosis (6,7). Furthermore, TN breast cancer is more common in familial breast cancer and tends to be of higher grade at diagnosis (8).…”

Section: Patients and Study Protocolmentioning

confidence: 99%

Triple-Negative and Non–Triple-Negative Invasive Breast Cancer: Association between MR and Fluorine 18 Fluorodeoxyglucose PET Imaging

Bolouri

Elias²,

Wisner³

et al. 2013

Radiology

View full text Add to dashboard Cite

Purpose:To assess the relationship between parameters measured on dynamic contrast material-enhanced (DCE) magnetic resonance (MR) imaging and fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in primary invasive breast cancer. Materials and Methods:This HIPAA-compliant study was a retrospective review of medical records and therefore approved by the institutional review board without the requirement for informed consent. Patients with a diagnosis of invasive breast cancer from January 2005 through December 2009 who underwent both DCE MR imaging and FDG PET/CT before treatment initiation were retrospectively identified. Fractional volumes were measured for ranges of signal enhancement ratio (SER) values from DCE MR imaging data and compared with maximum standardized uptake values (SUV max ) from FDG PET/CT data. Linear regression analysis was performed to clarify the relationship between SER and SUV max , adjusting for tumor size, pathologic grade, and receptor status. Results:Analyzed were 117 invasive breast cancers in 117 patients. Overall, a higher percentage of high washout kinetics was positively associated with SUV max (1.57% increase in SUV max per 1% increase in high washout; P = .020), and a higher percentage of low plateau kinetics was negatively associated with SUV max (1.19% decrease in SUV max per 1% increase in low plateau; P = .003). These relationships were strongest among triple-negative (TN) tumors (4.34% increase in SUV max per 1% increase in high washout and 2.65% decrease in SUV max per 1% increase in low plateau; P = .018 and .004, respectively). Conclusion:In invasive breast carcinoma, there is a positive relationship between the percentage of high washout and SUV max and a negative relationship between the percentage of low plateau and SUV max . These results are stronger in TN tumors.q RSNA, 2013 Supplemental material: http://radiology.rsna.org/lookup /suppl

show abstract

Section: Patients and Study Protocolmentioning

confidence: 99%

Triple-Negative and Non–Triple-Negative Invasive Breast Cancer: Association between MR and Fluorine 18 Fluorodeoxyglucose PET Imaging

Bolouri

Elias²,

Wisner³

et al. 2013

Radiology

View full text Add to dashboard Cite

show abstract

“…TNBC tumors have a relatively high rate of recurrence, distant metastases, and poor overall survival (1). TNBC is responsible for a large proportion of breast cancer deaths, despite its relatively small proportion among all breast cancers, due to its generally aggressive clinical course.…”

Section: Introductionmentioning

confidence: 99%

Inhibiting Aurora Kinases Reduces Tumor Growth and Suppresses Tumor Recurrence after Chemotherapy in Patient-Derived Triple-Negative Breast Cancer Xenografts

Romanelli

Clark

Assayag

et al. 2012

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Triple-negative breast cancers (TNBC) have an aggressive phenotype with a relatively high rate of recurrence and poor overall survival. To date, there is no approved targeted therapy for TNBCs. Aurora kinases act as regulators of mammalian cell division. They are important for cell-cycle progression and are frequently overexpressed or mutated in human tumors, including breast cancer. In this study, we investigated the therapeutic potential of targeting Aurora kinases in preclinical models of human breast cancers using a paninhibitor of Aurora kinases, AS703569. In vitro, AS703569 was tested in 15 human breast cancer cell lines. TNBC cell lines were more sensitive to AS703569 than were other types of breast cancer cells. Inhibition of proliferation was associated with cell-cycle arrest, aneuploidy, and apoptosis. In vivo, AS703569 administered alone significantly inhibited tumor growth in seven of 11 patient-derived breast cancer xenografts. Treatment with AS703569 was associated with a decrease of phospho-histone H3 expression. Finally, AS703569 combined to doxorubicin-cyclophosphamide significantly inhibited in vivo tumor recurrence, suggesting that Aurora kinase inhibitors could be used both in monotherapy and in combination settings. In conclusion, these data indicate that targeting Aurora kinases could represent a new effective approach for TNBC treatment. Mol Cancer Ther; 11(12); 2693-703. Ó2012 AACR.

show abstract

“…Further, TNBC is, only partially responsive to chemotherapy and presents a lack of clinically established targeted therapies. Consequently, only conventional chemotherapy is currently used in clinical practice and it effectiveness is limited [1]. Moreover, TNBC consist of two subtypes; basal and nonbasal type.…”

Section: Introductionmentioning

confidence: 99%

Clinicopathological Characteristics of Basal Type Breast Cancer in Triple-Negative Breast Cancer

Kutomi¹,

Ohmura²,

Suzuki³

et al. 2012

JCT

View full text Add to dashboard Cite

Background: Triple-negative breast cancer (TNBC) is defined by the absence of estrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor 2 (HER2) expression. Patients with TNBC derive no benefit from molecularly targeted treatments, such as endocrine therapy or trastuzumab, as they lack the appropriate targets for these drugs. TNBC is characterized by its biological aggressiveness and poor prognosis, and consists of two subtypes, basal and nonbasal. The purpose of our study is to differentiate the clinicopathological characteristics of the two subtypes. Methods: 367 patients with primary breast cancer were recruited from April 2004 to December 2010 at 1st Department of Surgery, Sapporo Medical University. ER, PgR, and HER2 status were evaluated in all cases. Moreover, we classified TNBC into basal, nonbasal subtypes on the basis of immunohistochemical staining of epidermal growth factor receptor (EGFR), cytokeratin (CK) 5/6. Basal type was defined as CK5/6-positive and/or EGFR-positive, and nonbasal type was defined as no expression of these two markers. Results: Breast cancer subtypes by molecular classification were Hormone receptor (HR)-positive/HER2-negative (61%), HR-positive/HER2-positive (10%), HR-negative/HER2-positive (14%), and HR-negative/HER2-negative (15%). There was no difference between the basal type and the nonbasal type in clinicopathological factors. But, the basal type was significantly associated with Ki67 labeling index (p = 0.0002), p53 expression (p = 0.047), and BRCA1 expression (p = 0.03). Further, patients with the basal type TNBC showed a shorter overall survival (p = 0.032) than did patients with the nonbasal type. Conclusion: Classification of TNBC subtypes by EGFR, CK5/6 is a very useful prognostic factor, and highlights the need for the development of an adequate new strategy for the basal type TNBC.

show abstract

Triple‐negative breast cancer: Present challenges and new perspectives

Cited by 268 publications

References 208 publications

Triple-Negative and Non–Triple-Negative Invasive Breast Cancer: Association between MR and Fluorine 18 Fluorodeoxyglucose PET Imaging

Triple-Negative and Non–Triple-Negative Invasive Breast Cancer: Association between MR and Fluorine 18 Fluorodeoxyglucose PET Imaging

Inhibiting Aurora Kinases Reduces Tumor Growth and Suppresses Tumor Recurrence after Chemotherapy in Patient-Derived Triple-Negative Breast Cancer Xenografts

Clinicopathological Characteristics of Basal Type Breast Cancer in Triple-Negative Breast Cancer

Contact Info

Product

Resources

About